Alkermes plc (NASDAQ:ALKS) just released its annual report and things are looking bullish. It was overall a positive result, with revenues beating expectations by 3.4% to hit US$1.6b. Alkermes ...

Alkermes upped its bid on Avadel to $2.37 billion on Wednesday, coming in with the "superior proposal" vs. Lundbeck's unexpected pitch.

The chair of an FDA panel believes the drug Dsuvia represents a “danger” to public health. Just two weeks after a rare rebuke from the Food and Drug Administration derailed Alkermes’s treatment for ...

(Reuters) - Drugmaker Alkermes said on Tuesday the U.S. Food and Drug Administration declined to approve its treatment for schizophrenia and bipolar disorder, citing concerns related to a tablet ...

Lundbeck has ended its bidding war with Alkermes to acquire Avadel Pharmaceuticals, saying that it will not increase its offer for the sleep disorder drug developer beyond the approximately $2.4 ...

Alkermes (ALKS) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.73 per share a year ago. These figures are ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...

Instead of the garden-variety symphony music favored by most pharma companies before entering a conference call, Alkermes selected Fleetwood Mac’s breakup anthem “Go Your Own Way.” It was a clever way ...

As biopharma grapples with a widespread gender diversity problem, Alkermes faces three lawsuits alleging discriminatory treatment toward female employees, with one suit even claiming it's the ...

This year, we’re celebrating 15 years of “Alkermes in Action,” our employee-led volunteer program that supports local non-profit organizations through hands-on activities. This month, more than 200 ...

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) today announced that Alkermes shareholders have approved the merger of Alkermes and Elan Drug Technologies (“EDT”), the profitable drug ...